West Virginia Medicaid Drug Utilization Review Board Minutes
September 25, 2024

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:
Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Michael Lonsinger, PharmD

Members Absent:
Lester Labus, MD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS

DHHR/BMS Staff:
Vicki Cunningham, PharmD, Director of Pharmacy
Kristen Boustany, PharmD
Hyla Harvey, MD, WV Medicaid Medical Director
Priya Shah, PharmD, Drug Utilization Review Coordinator
Doug Sorvig, Data Analyst

Contract Staff:
Joe Bergondo, PharmD – Change Healthcare
Roberta Capp, MD – Change Healthcare
Zach Garnes – Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health
Alena Mitchell, PharmD – Acentra Health

1. **INTRODUCTIONS**
    a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:02 PM (EST). The DUR Board and others introduced themselves.

2. **APPROVAL OF MINUTES FROM Sep 25th, 2024 DUR BOARD MEETING**
    a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.

3. **OLD BUSINESS**

a. None

4. **NEW BUSINESS**
    a. **Speakers**
        i. None
    b. **Updates from October 23rd, 2024 P&T Committee Meeting**
        i. Dr. Joe Bergondo presented the PDL status updates from the October 23rd, 2024 P&T meeting.
    c. **Prior Authorization Criteria.** Attachment A
        i. **Vancomycin solution and Firvanq:** approved as presented.
        ii. **Myhibbin:** approved as presented.
        iii. **Ohtuvayre:** approved as presented.
        iv. **SGTL2 non-preferred criteria:** approved as presented.
        v. **CGRP receptor antagonists:** approved with amendments.
            1. Changed criteria from requiring MIDAS or HIT-6 assessment on initial and reauthorization requests to either MIDAS/HIT-6 or decreased migraine frequency.
        vi. **Nexletol and Nexlizet:** approved with amendments.
            1. Added required LDL goals of <70 mg/dL and the goal set by the prescriber.
            2. Approval expanded to include new LDL goal criteria for all PCSK-9 inhibitors.
        vii. **Auvelity:** approved with amendments.
            1. Required trials of at least two chemically distinct antidepressant classes for at least 60 days each, one of which must be bupropion.
        viii. **Opzelura:** approved as presented.
        ix. **Cibingo:** approved as presented.
        x. **Rinvoq:** approved as presented.

5. **REPORTS – 3rd Quarter of 2024**
    a. **Gainwell Technologies Quarterly Report:** Mr. Zach Garnes presented an overview of the 2024 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
    b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the Third Quarter of 2024. Attachment C.
    c. **Acentra Health:** Dr. Alena Mitchell presented a summary of the RDUR interventions for the Third Quarter of 2024. Attachment D.

6. **OTHER BUSINESS**
    a. None

7. **NEXT MEETING AND ADJOURNMENT**
    a. The meeting concluded at 5:24 PM (EST).
    b. Next meeting on February 26th, 2025.